2020 - A general procedure to select calibration drugs for lab-specific validation and calibration of proarrhythmia risk prediction models: An illustrative example using the CiPA model

 icon sp96   SyncroPatch 768PE (a predecessor model of the SyncroPatch 768i instrument) publication in the Journal of Pharmacological and Toxicological Methods (2020)


Han X., Samieegohar M., Ridder B.J., Wu W.W., Randolph A., Tran P., Sheng J., Stoelzle-Feiz S., Brinkwirth N., Rotordam M.G., Becker N., Friis S., Rapedius M., Goteze T.A., Strassmaier T., Okeyo G., Kramer J., Kuryshev Y., Li Z.


Journal of Pharmacological and Toxicological Methods (2020) doi: 10.1016/j.vascn.2020.106890


In response to the ongoing shift of the regulatory cardiac safety paradigm, a recent White Paper proposed general principles for developing and implementing proarrhythmia risk prediction models. These principles included development strategies to validate models, and implementation strategies to ensure a model developed by one lab can be used by other labs in a consistent manner in the presence of lab-to-lab experimental variability. While the development strategies were illustrated through the validation of the model under the Comprehensive In vitro Proarrhythmia Assay (CiPA), the implementation strategies have not been adopted yet.

Download here.


We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.